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The MLL gene located at llq23 is frequently disrupted by chromosomal translocation in a wide spectrum of newly diagnosed acute leukemias. Recently, it has become apparent that the MLL gene is very frequently disrupted by chromosomal translocations in patients with secondary leukemias associated with chemotherapeutic regimens incorporating topoisomerase II inhibitors. These secondary leukemias associated with topoisomerase I 1 inhibitors (most commonly teniposide, etoposide, or doxorubicin) have distinct clinical and biologic features which have led to the speculation that they are induced by treatment with topoisomerase II inhibitors. We have identified a site within the MLL breakpoint cluster region (bcr) that is highly sensitive to double-strand DNA cleavage induced by topoisomerase II inhibitors. This finding is quite specific and highly reproducible. Although it UKARYOTIC TOPOISOMERASE I1 is a ubiquitously expressed enzyme capable of catalyzing the local changes in DNA topology that are required for normal DNA metabolism, including replication, transcription, and recombinati~n."~ Many of the most useful cancer chemotherapeutic agents are classified as inhibitors of topoisomerase 11, which seem to exert their cytotoxic effects not simply by inhibiting topoisomerase I1 function, but by converting topoisomerase I1 into a cellular poison.'.3 Topoisomerase I1 (topo 11) inhibitors cause an accumulation of enzyme-DNA covalent intermediates ("cleavable complexes"), leading to an accumulation of DNA-double strand breaks. The observation that tumors with higher levels of top0 II (such as rapidly proliferating, clinically aggressive malignancies) are more sensitive to top0 I1 inhibitors supports the notion that top0 I1 inhibitors actually function by corrupting the enzyme..' Top0 I1 inhibitors can be placed into distinct classes based on their structure and proposed mechanism of action.".' Two of the most clinically useful top0 I1 inhibitors are doxorubicin and etoposide, representative of the anthracyclines and epipodophyllotoxins respectively. Despite the unquestioned clinical utility of these compounds, it has recently become apparent that several drugs classified as top0 I1 inhibitors, such as doxorubicin, etoposide, and teniposide,'"' are associated with the development of secondary leukemias." The presence of consistent biologic and clinical findings have suggested that these secondary leukemias are causally associated with the use of these top0 I1 inhibitor^.^,^,^." This suggestion is strengthened by the observation that top0 I1 inhibitors can induce a spectrum of gross chromosomal abnormalities such as translocations, inversions, and deletions in peripheral blood lymphocytes PBLs.".I3
Secondary leukemias associated with top0 I1 inhibitors have distinct clinical and biologic features. They most commonly occur within 3 years of treatment, are usually not associated with preceeding myelodysplasia, often have monocytic features, and commonly show a cytogenetic abnormality at chromosome 1 I band q23,',7,ii The MLL geneL4 (also known as ALL-1" or H M I 6 ) is almost always disBlood, Vol 87, No 7 (April l), 1996: pp 2649-2658 E was initially discovered in malignant lymphoblasts isolated from a patient receiving multiagent chemotherapy, this sitespecific double-strand DNA cleavage can be induced in tissue culture using malignant cell lines as well as peripheral blood from normal individuals. Site-specific cleavage occurs in a significant fraction of cells using a variety of model systems, is both time and dose dependent, and can be induced with either doxorubicin or etoposide. This site-specific cleavage maps to the same region as a consensus topoisomerase II cleavage site within the MLL bcr. These results suggest that site specific cleavage within the MLL bcr induced by topoisomerase II inhibitors may be an early step leading to MLL translocations and secondary leukemia. 0 1996 by The American Society of Hematology.
rupted by these l lq23
These breakpoints are similar to those reported for de novo leukemias, generally occurring within an 8.3-kb breakpoint cluster region (b~r).''"~ There is consistent retention of the derivative 11 chromosome and production of in-frame fusion mRNAs between M U and numerous different partner genes.I5'l7 It has been proposed that top0 I1 inhibitors induce chromosomal breakage within the MLL gene, with MLL translocations resulting from mistakes in the DNA repair process.8 The resultant MLL fusion proteins produced by the translocations are thought to be causal factors in the development of these secondary leukemias.
Although there is circumstantial evidence to support this hypothesis, specific MLL gene fragmentation or rearrangement directly induced by top0 I1 inhibitors has not been convincingly demonstrated. Given the widespread use and clinical utility of top0 I1 inhibitors, it is important to understand the relationship between top0 I1 inhibitors, MLL gene disruption, and secondary leukemias. As an initial step in understanding this relationship, we describe here the identification and characterization of a site within the MLL breakpoint cluster region that is highly sensitive to doublestrand DNA cleavage induced by top0 I1 inhibitors in vivo.
use only. 
MATERIALS AND METHODS
Patient samples and cell lines. The patient (RUPN78) was a 14-year-old white male with T-cell acute lymphoblastic leukemia (T-ALL) who presented with a white blood cell (WBC) count of 189,OOO/pL (88% lymphoblasts), a hemoglobin (Hb) level of 12.0 g/&, and a platelet count of 102,OOO/pL. Bone marrow (BM) aspiration demonstrated greater than 95% lymphoblasts with T-cell immunophenotype (CD2,5,7,4+, CD3,8-) and a normal karyotype (46,XY). Informed consent to participate in research studies was obtained in accordance with institutional guidelines, and multiagent chemotherapy was instituted consisting of doxorubicin (50 mg/m2), cyclophosphamide (1,OOO mg/m2), vincristine (l .5 mg/m*), and prednisone (40 mg/m2). PB was inadvertantly obtained 16 hours after institution of chemotherapy rather than before chemotherapy; the WBC count at the time this sample was collected was 60,2OO/bL. Lymphoblasts were isolated using Ficoll-Hypaque (Sigma, St Louis, MO) density centrifugation.
The cell lines used in this study were CEM, HSB-2, Molt4, Jurkat, PEER, SUPTI1 (all T-cell leukemidymphoma); Raji, Daudi, NALM6, BALLI, (all malignant B-lymphocyte origin); ML-1, KG-I , and HL60 (primitive myeloid), U937 (monocytic), HEL (erythroleukemia), K562 (chronic myelogenous leukemia), HeLa (cervical carcinoma), CHP134 and CHPlOO (both neuroblastoma), H69 (small cell lung cancer), 5637 (bladder carcinoma), and HT1080 (fibrosarcoma). A list of references describing these cell lines is available upon written request.
DNA isolation and Southern blotting. DNA and RNA was extracted from the RUPN78 patient sample by lysis in 4 molL guanidine isothiocyanate containing 10 pg/mL ethidium bromide (used to visualize genomic DNA) and ultracentrifugation over a 5.7 mom CsCl gradient, as previously described." DNA from cell lines was extracted using a salting out procedure that did not expose the cells to ethidium bromide." Cells were pelleted and resuspended in 3 mL lysis buffer (0.2 m o m NaCI, 20 mmoVL EDTA, 40 mmoVL Tris pH 7.6,0.5% sodium dodecyl sulfate [SDS] , and 133 pg/mL proteinase K) and incubated at 50°C for 3 hours. RNase A was added to a final concentration of 10 pg/mL and the sample incubated at 37°C for 30 minutes. One and one-half milliliters of saturated NaCl (approximately 6 mom) was added, and the sample centrifuged at 3,OOOg. The supernatant was aspirated and DNA spooled out of solution after precipitation with 2 v01 of ethanol.
Ten micrograms of genomic DNA was digested with the indicated restriction enzymes (BRL, Gaithersburg, MD), size-fractionated on 0.8% agarose gels containing 10 pg/mL ethidium bromide, photographed, denatured, neutralized, and transferred to nitrocellulose?" DNA was immobilized by UV cross-linking.
Probes and hybridizations. The MLL probes used in this study were the following: a 0.7-kb cDNA fragment encompassing MLL exons 5-7 and 9-1 1: ' a 0.3-kb exon 5 fragment (nucleotides 1-303 of Genbank accession no. U04737), a 0.2-kb Hha I-BamHI cDNA fragment encompassing exons 9-1 I (nucleotides 4207-4423 of Genbank accession no. L04731), a 0.9-kb exon 3 genomic fragment (nucleotides 1054-1985 of Genbank accession no. L04731), and a 0.5-kb genomic probe located 6 kb 3' of the MLL bcr. Additional probes used were a 2.2-kb SCL genomic a 0.4-kb cmyc genomic fragment? a 0.5-kb W -6 genomic probe, a 0.6-kb ENL probe;' a T-cell receptor 6 (TCRD) J61 probe,26 a T-cell receptor p (TCRB) Cp2 probe," a T-cell receptor y (TCRG) Cy 1 probe,Ix and a 1.5-kb genomic probe from an as-yet-unnamed region telomeric of MLL involved in a complex MLL rea~~angement.'~ Probes were 32P-labeled using a Prime-It I1 kit (Stratagene, La Jolla, CA) following the manufacturer's recommended procedure. Southern blot hybridizations were performed as previously described:' with the final stringency washes consisting of 0.1% SDS and 0.1 X SSC (1 X SSC = 0.15 mol/L NaCl + 0.015 mol/L sodium citrate) at 52°C. The blots were autoradiographed for I to 5 days at -70°C with an intensifying screen.
Top0 II inhibitor treatment of cell lines and PBLs. All chemotherapeutic agents were purchased from Sigma. Etoposide was &S-solved in dimethyl sulfoxide (DMSO) at a stock concentration of 100 mmol/L. Doxorubicin was dissolved in sterile H20 at a stock concentration of 2 mg/mL. Vincristine was dissolved in sterile H 2 0 at a stock concentration of I mg/mL. Prednisone was dissolved in 50% ethanol at a stock concentration of 1 mg/mL. Melphalan was dissolved in propylene glycol at a stock concentration of 0.5 mg/ mL. Exponential growth phase cells were washed and resuspended at 5 X 10' cells/mL and immediately treated with the indicated chemotherapeutic agent. After a 16-hour continuous exposure to the chemotherapeutic agent or control, genomic DNA was obtained for Southem blot analysis. PB mononuclear cells (PBMNCs) obtained from normal volunteers were incubated in RPMI 1640 supplemented with 10% fetal calf serum for 36 hours in the presence or absence of 1% crude phytohemagglutinin (PHA) (BRL). The cells were then washed, resuspended in RPMI 1640 and fetal calf serum, and treated with either 100 p m o m etoposide or DMSO for 16 hours.
RESULTS
Site-spec$c cleavage of the MLL locus induced by multiagent chemotherapy. During the course of a study designed to characterize molecular lesions present in T-cell acute lymphoblastic leukemia (T-ALL) patients at diagnosis, we studied T-lymphoblasts from a T-ALL patient (RUPN no. 78) obtained 16 hours after the institution of combination chemotherapy consisting of vincristine, doxorubicin, cyclophosphamide, and prednisone. Because most MLL gene rearrangements cluster within an 8.3-kb genomic DNA breakpoint cluster region (MLL bcr),"~** and can be detected by a 0.7-kb cDNA probe that encompasses this fragment, we screened genomic DNA extracted from patient lymphoblasts for MLL gene rearrangements by Southern blot using this 0.7-kb cDNA fragment. The results shown in Fig  1 initially suggested that an MLL rearrangement had OCcurred, with rearranged bands seen using four different restriction enzymes (see arrows). However, the intensity of the rearranged bands compared with the germline bands was significantly lower than expected, and made us question this interpretation. The trivial possibilities of partially digested genomic DNA, or restriction enzyme "star" activity were ruled out by rehybridization of the blot to several control probes (data not shown). The possibility that the PB sample was heavily contaminated with nonmalignant cells diluting the signal from lymphoblast DNA seemed unlikely because the WBC count was >h0,000 cellslpL, with more than 90% lymphoblasts at the time the sample was obtained. The possibility of an MLL gene reamngement developing in a subclone of the original leukemic clone seemed unlikely, as this has not been described in T-cell ALL, but could not be excluded.
Close inspection of the sizes of the rearranged fragments suggested an alternate explanation. The sum of the rearranged fragments present in the BnrnHI digest, 6.7 and 1.5 kb, was quite close to the total 8.3-kb BnrnHl germline fragment. This suggested that these rearranged fragments may have been generated by a double-strand break within the 8.3-kb BnnlHI fragment, producing hybridizing fragments of 6.7 and 1.5 kb. If this explanation is correct, one end of each rearranged fragment would be produced by the indicated restriction enzyme, whereas the other end would be produced by a site-specific double-strand DNA break. The pattern of rearranged fragments seen in Fig IB is entirely consistent with a highly specific DNA double-strand break occurring at the site indicated in Fig 1A. We suspect that this cleavage was caused by the 16-hour exposure to multiagent chemotherapy; unfortunately, DNA from leukemic lymphoblasts obtained before therapy was unavailable for study. Assuming that double-strand cleavage was induced by multiagent chemotherapy with vincrisitine, doxorubicin, cyclophosphamide. and prednisone, the top0 I1 inhibitor doxorubicin would seem to be the most likely cause, although we cannot exclude the possibility that vincristine, cyclophosphamide, or prednisone induced the double-strand break. An identical MLL clenvage pattern can he induced in T-ALL cell lines by topo I1 inhibitors. To develop a model system in which this phenomenon could be more completely characterized, we treated several hematopoietic cell lines for 16 hours with the top0 I1 inhibitors doxorubicin or etoposide. Figure 2 shows that an identical, specific double-strand DNA break within the MLL locus can be induced by either doxorubicin (Fig 2A) or etoposide (Fig 2B) in the T-ALL cell line CEM. An identical pattern was seen with the T-ALL cell line Molt4 (data not shown) treated with either doxorubicin or etoposide. We also treated the CEM cell line with vincristine (0.06 &mL) or prednisone (2.0 pg/mL) to determine if these agents also could induce site-specific MLL cleavage. Because cyclophosphamide is inactive in vitro, we treated CEM cells with melphalan (0.5 pg/mL) as an alternate alkylating agent. Although a cytogenetic study suggested that melphalan induced chromosome breakage at several chromosomal regions, including 1 Iq,'" treatment with these agents did not induce site-specific MLL cleavage (data not shown).
The cDNA probe used in Fig 1 hybridizes to fragments on either side of the proposed double-strand break. To confirm the mapping of this double-strand break, we generated a 303-bp MLL exon S probe, as well as an MLL cDNA probe that encompassed exons 9. IO. and I I (probe 0.2HB). Figure  3 shows that the exon 9-1 1 probe hybridizes only to the bands predicted by the map presented in Fig IA. The exon S probe also hybridized only to the bands predicted by the map shown in Fig IA (data not shown) . Analysis of multiple digests and multiple gels indicated that the double-strand break consistently maps to a region 1,500 bp S' of the 3' RarnHl site bounding the MLL breakpoint cluster region (see Fig IA) . Interestingly, the 8.3-kb MLL breakpoint cluster region has been completely sequenced,3" and found to contain a single match (nucleotides 6857-6874 of Genbank accession no. U04737) to the top0 I1 consensus recognition sequence (5'-A/GNT/CNNCNNGT/CNGGITTNT/CNT/C-3'):'' located 1470 bp S' of the 3' RarnHl site bounding the MLL breakpoint cluster region. We conclude that the rearranged bands seen in DNA extracted from cell lines treated with the top0 I1 inhibitors etoposide or doxorubicin are caused by a very specific, high-frequency double-strand DNA break within the MLL locus.
To rule out the possibility that the MLL cleavage was an artefact generated by ethidium bromide used either in genouse only. mic DNA preparation or agarose gel electrophoresis, we repeated these experiments with procedures that did not use ethidium bromide in either DNA preparation or electrophoresis. The results were identical to those obtained with procedures that used ethidium bromide (data not shown).
Specifc MLL double-strand DNA cleavage occurs in a time and dose-dependent fashion. Because epipodophyllotoxins such as etoposide are the agents most frequently implicated in secondary AML associated with MLL gene rearrangements," we focused on the epipodophyllotoxin etoposide as the topo 11 inhibitor in subsequent studies. Figure 4 shows that specific double-strand DNA cleavage can be induced with etoposide concentrations as low as 3.0 pmol/ L, and that the site-specific DNA cleavage increases with increasing doses, reaching a plateau between 30 and 100 pmol/L. The Molt4 cell line was somewhat more sensitive in this assay, and site-specific double-strand cleavage could be detected with an etoposide concentration as low as 1.0 pmol/L (data not shown). The MLL double-strand break does not occur immediately in the majority of CEM cells, as shown in Fig S. A sufficient number of cells have developed the double-strand DNA break to allow a faint band to be visualized at 4 hours, and a clear signal can be detected 8 of the MLL bcr. A O.SIkb genomic Ec6RI fragment 6 kb 3' of the MLL bcr was isolated from an MLL genomic phage clone. These fragments did not detect a fragile site within 29 and 14 kb S' and 3', respectively, of the MLL bcr. We also were unable to detect etoposide induced fragile sites using probes from the SCL, AF-6. ENL, TCRB, TCRG, or TCRD loci, as well as an as-yet-unnamed region telomeric to MLL on 1 Iq that is rearranged in a complex MLL translocation (see methods for description of probes).
We rehybridized several of our Southern blots demonstrating site-specific cleavage within the MLL bcr to a c-myc probe, as an assay very similar to ours32 has identified several in vivo cleavage sites induced by top0 I1 inhibitors within the human c-myc promoter. It is important to note that the assay performed in that study used a cell line (NCI-N417) that has a marked amplification of the c-myc transcript unit (40 to SO copies). We were unable to detect any evidence of specific c-myc promoter fragmentation in the cell line or patient samples we used (data not shown). This result is not surprising in light of the fact that the fragments induced by top0 I1 inhibitors in the referenced experiments:" which used a cell line containing 40 to SO copies of the c-myc transcript unit, were only faintly visible on Southern blots.
Site-specific MLL cleavage is inducible in a spectrum of cell lines. We treated several hematopoietic and nonhematopoietic cell lines to determine if specific MLL doublestrand DNA cleavage is a generalizable phenomenon. We were able to clearly identify an identical pattern of sitespecific MLL cleavage in 4 of 6 malignant T-cell lines tested, 3 of 4 malignant B-cell lines, 1 of 6 myeloid leukemia cell lines, and 1 of 6 solid tumor cell lines (Table l) . This limited survey of cell lines indicates that site-specific MLL cleavage in response to epipodophyllotoxins is not unique to T-ALL, and suggests that ALL cell lines may be more likely to demonstrate site specific MLL cleavage than other malignant cell lines. In addition, Table 1 shows that, in general, there is a good correlation between site-specific MLL cleavage and cytotoxicity due to epipodophyllotoxins.
To determine if this phenomenon was unique to malignant use only. Although not as extensive as the site-specific cleavage detected in cell lines, we were able to detect site-specific MLL gene cleavage in both PHA-activated and unactivated PBMNCs treated with etoposide in vitro (site-specific cleavage of unactivated PBMNCs is shown in Fig 6) .
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DISCUSSION
Secondary leukemias associated with the use of topo I1 inhibitors, especially the epipodophyllotoxins teniposide and etoposide, have reproducible clinical, immunophenotypic, and genetic feature^.^.'"." The consistent association of epipodophyllotoxin induced secondary leukemias with MLL gene translocation suggests that MLL translocations are causative events for these secondary leukemias.'."' The clinical relevance of this topic is underscored by a recent study of Bcell precursor ALL therapy where more children developed secondary AML than relapsed with ALL." Given the extraordinary clinical utility of topo I1 inhibitors, it is imperative that the molecular mechanism underlying these MLL translocations, and their relationship to topo I1 inhibitors. be elucidated in a timely fashion. As an initial step in understanding this mechanism, we have demonstrated a site within the MLL breakpoint cluster region that is uniquely sensitive to cleavage induced by topo 11 inhibitors in vivo. Although we have not mapped the cleavage site precisely, it is interesting use only. Exponential growth phase cells were incubated for 16 hours in the presence of 10 pmollL etoposide or vehicle (DMSO) alone. Viability was assayed by trypan blue exclusion. Site-specific cleavage within the MLL bcr was determined by Southern blot.
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Abbreviations: CML, chronic myelogenous leukemia; SCLC, small cell lung cancer; ND, not done.
Interpretation of the ML-1 cell line Southern blot pattern was complicated by the fact that ML-1 has both an MLL translocation and detection (Strout et al. submitted for publication).
to note that this cleavage site maps to the same region as the only consensus top0 I1 cleavage site within the 8.3-kb MLL bcr."
This site specific DNA cleavage is highly reproducible in tissue culture. We have shown that it is not an artefact dependent on the use of ethidium bromide (a known DNA intercalator but a poor inhibitor of top0 11) in either DNA extraction or electrophoresis. We have also generalized this process from a clinical observation to a phenomenon that is highly reproducible in tissue culture. This site-specific cleavage, similar to other effects of the epipodophyllotoxins, such as the induction of apoptosis,33 and cytotoxicity, is dependent on the concentration of epipodophyllotoxin. Depending on the cell line studied, an effect is noted at concentrations as low as 1.0 pmol/L etoposide, with increasing site-specific cleavage seen with increasing etoposide concentration until a plateau at 30 pmol/L is reached. The site-specific MLL cleavage is not detectable in our assay until 4 hours after treatment: maximal cleavage is seen after 24 hours, with no further increase detected with incubation times up to 72 hours. The cause of the delay is unclear; it may be that cells in a certain phase of the cell cycle are most sensitive. A wash-out experiment indicated that a l-hour exposure to etoposide was sufficient to cause this site-specific cleavage, although the cleavage was not as extensive as that seen with a 16-hour continuous exposure to the same concentration of etoposide.
Although we have evaluated this phenomenon primarily in T-ALL cell lines, the site-specific cleavage is not unique to cells of T-lymphocyte origin, or even to hematopoietic cells. Our preliminary survey indicated we could detect varying degrees of cleavage in most T-ALL cell lines tested (Table I) correlate well with drug toxicity. With few exceptions, cell lines that displayed site-specific cleavage were sensitive to etoposide, whereas cell lines that did not display doublestrand DNA cleavage were relatively resistant to the cytotoxic effects of etoposide. Although the fraction of cells displaying the site-specific double-strand break was not as great as with T-ALL cell lines or patient samples, we were also able to detect site specific cleavage in nonmalignant PBMNCs from normal volunteers.
We have been unable to detect any other genomic regions as sensitive to top0 I1 inhibitor-induced cleavage as the MLL bcr. A specific region of the c-myc promoter was shown to be sensitive to top0 I1 inhibitor induced cleavage using an assay very similar to ours3'; however, those investigators were only able to detect in vivo cleavage using a cell line amplified for c-myc. We were unable to detect any specific top0 I1 inhibitor induced cleavage using cell lines that were not amplified for c-myc. We also were unable to detect specific cleavage either 5' or 3' of the M U bcr. Similarly, we were unable to detect specific DNA cleavage at several other loci (SCL, ENL, AF-6, TCRB, TCRG, TCRD, and an asyet-uncharacterized region distal to MLL on 1 lq23). This is not to say that other sites equally sensitive and specific as the site within the MLL bcr are not present throughout the genome; however, we have yet to identify them. There is evidence that chromosomal DNA can be separated into loops or domains of 5 to 200 kb in length by its attachment to the nuclear matri~.'~ Top0 11, which has been shown to be a component of nuclear matri~,'~ is thought to be a structural component of the nuclear attachment regi~n.~'.~' It is possible that this sensitive site corresponds to a nuclear attachment region, and one end of one of these 5 to 200-kb loops.
The site-specific cleavage that we have demonstrated occurs in vivo. A recent study, using naked DNA (an endlabeled fragment of MLL intron 6 genomic sequences), has identified a cluster of sites within MLL intron 6 that are sensitive to cleavage induced by top0 I1 inhibitors in However, our in vivo assay did not identify any cleavage sites induced by top0 I1 inhibitors within intron 6. There are several potential explanations for this apparent inconsistency. The previous study did not investigate potential top0 I1 sensitive sites located in the vicinity of the site we have identified; it remains possible that the cleavage site we have identified would score as strongly positive in their in vitro assay. A second possible explanation stems from the observation that the teniposide-induced in vitro and in vivo DNA cleavage patterns of Drosophila histone genes were found to be markedly different. 39 An explanation offered for that inconsistency was that the in vitro cleavage sites map to genomic regions that are inaccessible in vivo, possibly because of steric hindrance by nucleosomes.39 Therefore, at least with the Drosophila histone genes, it appears that in vitro top0 I1 inhibitor induced cleavage sites do not always predict in vivo cleavage sites. An additional explanation might be the specific cleavage we detect is not a direct result of topo I1 inhibition, but is instead a downstream event caused indirectly by top0 I1 inhibition. Indeed, several studies have suggested that the cytoxicity of topo I1 inhibitors can be dissociated from the generation of DNA doublestrand breaks, and secondary events are required for cell death.40*4' One likely candidate for such a downstream event is activation of apoptosis, which is also associated with DNA fragmentation." ' An additional point regarding the observation of site-specific cleavage within the MLL bcr concerns MLL genotyping studies. The MLL probes and digests we used are commonly used to detect MLL gene rearrangements in both ALL and AML patients. The pattern we saw in our index patient (Fig  l) , who had been treated 16 hours before sample collection, may easily be misinterpreted as demonstrating a MLL gene rearrangement, leading to misclassification of the patient's MLL gene status.
Our working hypothesis that relates the discovery of sitespecific cleavage within the MLL bcr to secondary leukemias is as follows: Top0 I1 inhibitors induce site-specific doublestrand DNA breaks within the MLL bcr, either directly or indirectly, in normal hematopoietic precursor cells. The vast majority of these cells either successfully repair the break, or are unable to completely replicate their DNA and die. However, in an abortive attempt to repair the double-strand DNA break within the MLL bcr, translocations or deletions may rarely occur if the repair is not completed properly. The cells containing rearrangements within the MLL bcr then have a proliferative advantage conferred by the MLL translocation, and that proliferative advantage is seen clinically as a secondary leukemia. One corollary of this model is that MLL breakpoints from patients with secondary leukemias might cluster near this region of site-specific cleavage within the M U bcr. 
